Table 5.

The significance of TSR in 838 EOC patients according to different subgroup using multivariate Cox survival analysis.

Variable	Cases (N)	TR (N)	TD (N)	TSR
				Progression-free survival (PFS)			Overall survival (OS)
				HR	95% CI	P	HR	95% CI	P
Histology
Serous	599	533	422	1.873	1.564–2.242	<0.001	2.075	1.702–2.530	<0.001
Mucous and others	239	217	188	1.616	1.210–2.157	0.001	1.860	1.348–2.567	<0.001
FIGO stage (2009)
I-II	243	210	155	1.065	0.765–1.481	0.710	1.038	0.705–1.528	0.849
III-IV	595	540	455	2.058	1.726–2.455	<0.001	2.302	1.904–2.783	<0.001
LN metastasis
No	657	572	451	1.276	1.082–1.505	0.004	1.818	1.492–2.216	<0.001
Yes	181	178	159	2.156	1.588–2.926	<0.001	2.555	1904–2.783	<0.001
Residual disease
<1 cm	631	561	451	1.961	1.646–2.337	<0.001	2.167	1.790–2.624	<0.001
≥1 cm	207	189	159	1.387	1.015–1.896	0.040	1.607	1.135–2.276	0.007

TSR: tumor-stroma ratio; TR: tumor recurrence; TD: tumor-related death; LN: lymph node; HR: hazard ratio; CI: confidence interval; P: P value, Cox regression.